FibroBiologics (FBLG)
Develops allogeneic fibroblast therapies for diabetic foot ulcers and other chronic diseases.
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a topically applied allogeneic cell therapy that uses donor fibroblasts, a type of specialized connective tissue cell, to accelerate wound healing.
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product and its shipment to Australia in support of the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use.
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regarded as the most influential sports agent of his generation, Mr.
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroids HOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthrough in its orthopedics laboratory using chondrocyte spheroids to treat degenerative joints. Degenerative joint disease affects millions of people worldwide and is one of the leading causes of chronic pain and disability.
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathways HOUSTON, Aug. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office (EPO) has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells." The granted patent, European Patent No.
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On track for interim results reporting in 2H 2026 HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. Recent Highlights: Clinical Updates: Initiation of patient dosing in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute for Space and Global Biomedicine Joins Board HOUSTON, July 9, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Kathleen "Kate" Rubins, Ph.D. to its Board of Directors.
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with cGMP standards and is undergoing the required safety and quality testing ahead of release for clinical use.
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, and Chief Scientific Officer, Hamid Khoja, Ph.D., will participate in a fireside chat at the H.C.
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that the first patients have been dosed in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). Initial dosing took place during the week of June 1, 2026.
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the first patients have been enrolled and dosed in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) titled “Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same” covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract. The provisional patent application describes an oral administration platform intended to deliver fibroblasts and fibroblast-derived therapeutics, including whole cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, to the GI tract using encapsulation materials and enteric coatings engineered to preserve viability and bioactivity during transit.
FibroBiologics CEO Issues Letter to Shareholders
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders. Dear Fellow Shareholders, This year, FibroBiologics achieved a milestone we have been working toward over the past few years.
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the presentation of preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting taking place May 13-15, 2026, in Chicago, Illinois.